AbbVie Wants Out Of Testosterone MDL Before Bellwethers

Law360, Chicago (February 22, 2017, 4:58 PM EST) -- AbbVie Inc. and Abbott Laboratories asked an Illinois federal judge Monday to let them out of a massive multidistrict litigation over the marketing and sale of testosterone gel products, arguing the consumers haven't shown a connection between the drug and the alleged increased risk of heart attack and stroke.

In a motion for summary judgment filed ahead of several bellwether trials testing claims on AbbVie and Abbott's product AndroGel, the drugmakers said there is no evidence the consumers' use of AndroGel caused their heart problems.

"Because plaintiffs have failed to meet their burden of demonstrating that their experts' specific causation opinions...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!